羟苯磺酸钙对血液流变及血栓形成作用的实验研究

目的研究国产抗糖尿病微血管病变药物羟苯磺酸钙对血小板聚集、血栓形成、血液粘滞度、红细胞脆性以及出血时间等影响 ,为临床应用提供理论依据。方法与结果羟苯磺酸钙0.15、0.21和0.30g/kg,灌胃 ,每日1次 ,连续3d ,可明显抑制ADP和胶原引起的大鼠血小板聚集 ,其抑制率与对照组比较有显著性差异(P<0.01) ;明显降低大鼠血液粘滞度及改善大鼠红细胞中间脆性 ,其作用与对照组比较均有显著性差异(P<0.01)。羟苯磺酸钙0.15、0.30和0.60g/kg灌胃 ,一次给药 ,可明显抑制大鼠颈动静脉旁路血栓形成 ,其作用呈剂量依赖性 ,与对照组比较有显著性差异(P<0.01 ,P<0.05) ;对于小鼠 ,羟苯磺酸钙0.15、0.30和0.60g/kg 灌胃 ,一次给药 ,可明显对抗胶原诱导的血栓形成 ,其降低血栓引起的死亡和偏瘫率呈剂量依赖性 ,与对照组比较有显著性差异(P<0.01 ,P<0.05) ;能明显延长小鼠出血时间 ,与对照组比较有显著性差异(P<0.01)。结论羟苯磺酸钙对于糖尿病微血管病变相关的血液学指标有改善作用。

Research on the Action of Hemorheology and Anti- thrombosis of Calcium Dobesilate

Objective To evaluate the actions of the domestic anti-diabetic microangiopathy drug,calcium dobesilate on platelet aggregation,thrombosis,blood viscosity,erythrocyte fragility and bleeding time,offering pharmacological data for clinical use.Methods and Results Calcium dobesilate0.15?0.21and0.30g/kg,i.g,qd for3days sighificantly reduced platelet aggregation induced by ADP and collageln,and decreased blood viscosity and erythrocyte intermediate fragility of the rats.These results were significantly different fromthose in the control group(P<0.01).One dose of0.15?0.30or0.60g/kg of calciumdobesilate inhibited thrombosis in the carotid artery and cervical vein bypass which was dose_dependent,and significantly different fromthose in the control group(P<0.01).In mice,treatmentwith0.15?0.30or0.60g/kg of the drug also inhibited thrombosis induced by collagen and decreased mortality and morbidity of hemiplegia(P<0.01and P<0.05respectively)and prolonged bleeding time(P<0.01),which were significantly different fromthose in the control group.Conclusions Calcium dobesilate plays a significant role in hemorheological data which are correlated with diabetic microangiopathy.